Recently, Beijing Yanming Biotechnology Co., Ltd. was co-founded by Shao Feng, the winner of the Zhongguancun Award for Outstanding Contribution, the highest award of the Beijing Science and Technology Award, academician of the Chinese Academy of Sciences, deputy academic director of the Beijing Institute of Life Sciences Technology Co., Ltd. (hereinafter referred to as Yanming Bio) announced that the company has made breakthrough progress in developing a new drug molecule project targeting Gasdermin family proteins to inhibit pyroptosis.
The so-called cell pyroptosis, also known as cell inflammatory necrosis, is a kind of programmed cell death, which is characterized by the continuous expansion of cells and the final rupture of the cell membrane. If cancer cells undergo pyroptosis, perhaps the cancer cells will trigger stronger anti-tumor immunity, so that cancer treatment can be achieved.
This is not a fantasy. As early as 2015, Shao Feng and his team published a paper in Nature, revealing for the first time that Gasdermin D (GSDMD) is the executor of pyroptosis (GSDMD is a member of the Gasdermin family of proteins, which also includes GSDMA, GSDMB , GSDMC, GSDME and DFNB59), and it was found that the N-terminal domains of this family members (except DFNB59) have the function of inducing pyroptosis. The above-mentioned discovery was rated as one of the 20 landmark developments in the field of immunology in the past 20 years by the journal Nature Reviews Immunology.
In 2020, Shao Feng and Dr. Deng Tianjing jointly founded Yanming Biological Company based on original results such as innate immunity and pyroptosis pathways, and are committed to the development of revolutionary innovative drugs for inflammation and tumors.
According to reports, the high-affinity small molecule inhibitor of pyroptosis developed by Yanming Biotechnology recently analyzed the high-resolution crystal structure of the gasdermin protein and small molecule inhibitor complex for the first time in the world, revealing the A new mechanism of action on how small molecule drugs can inhibit the membrane hole-perforating function of Gasdermin protein.
Studies have shown that Gasdermin family proteins play a role in sepsis, multiple sclerosis, asthma, inflammatory damage caused by chemotherapy drugs, viral infections, or cytokine storm and IBD caused by CAR-T treatment. play a key role in various inflammatory diseases. Therefore, the development of specific Gasdermin inhibitors will provide new solutions for the treatment of these diseases.
Shao Feng said, “Our latest breakthrough shows that it is completely feasible to develop specific small molecule inhibitors for Gasdermin family proteins, including GSDMD, and our research also provides a clear technical route for this. "
"This is the world's first inhibitor targeting the Gasdermin protein." Deng Tianjing, CEO of Yanming Biotech, said, "From the time we found the clue compound to increasing its activity on cells hundreds of times, and in and disease It only took just one year to obtain nanomolar-level compounds on disease-related primary cells until we finally obtained the high-resolution structure of its binding to protein . "
" At the same time, Deng Tianjing introduced, "From HTS (Qualcomm). quantitative drug screening) to obtain the first international It only took us 6 months to develop the eutectic structure of the complex. These results verify Yanming Bio’s drug research and development capabilities, and also prove that we can develop new drugs from 0 to 1 in China.” MingBio has also made significant progress in other natural immune regulation projects. Deng Tianjing revealed that Yanming Biotech is currently conducting multiple new drug research and development projects with new targets and new mechanisms of action, and some projects have entered the pre-clinical research stage.
It is reported that Yanming Biotech is headquartered in Zhongguancun Life Science Park, Beijing. It is a key enterprise supported and cultivated by Beijing. The R&D center covers an area of 3,400 square meters, equipped with world-class R&D equipment, and has medicinal chemistry, computational chemistry, discovery New drug research and development capabilities such as biology, structural biology, pharmacodynamics and pharmacokinetics. Currently, nearly 100 scientific researchers are working on the research and development of new drugs for multiple new targets here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-